What Causes False Positives on Fentanyl Test Strips

Fentanyl test strips use a competitive binding immunoassay. The test antibody is designed to bind fentanyl with high affinity and specificity. At the validated concentration range (approximately 2 mg/mL of dissolved substance), the antibody can distinguish fentanyl from the hundreds of other compounds that might be present in a drug sample. But antibody specificity is not absolute — it is concentration-dependent. At high sample concentrations (10+ mg/mL), molecules that share even partial structural similarity to fentanyl can saturate the antibody binding sites through mass action. If enough non-fentanyl molecules are present at high enough concentration, some will bind the antibody, preventing the colloidal gold conjugate from reaching the test line and producing a false positive signal. This phenomenon has been documented in published research. Krieger et al. (2021) in Harm Reduction Journal demonstrated that high concentrations of various substances produced false positive results on fentanyl test strips. The critical variable was concentration — when diluted to the proper range, the same samples tested negative.

When fentanyl test strips were first repurposed from clinical urine testing to drug checking in the late 2010s, there were no standardized instructions for this new use case. Harm reduction organizations wrote their own guides, often based on intuition rather than analytical chemistry. Early instructions typically asked users to scoop "about 10 milligrams" of substance — described variously as "a match head," "the size of Lincoln\'s hair on a penny," or simply "a small amount." These visual estimates are wildly imprecise. A 2025 thematic content analysis published in Harm Reduction Journal examined 16 different sets of fentanyl test strip instructions and found enormous variability in recommended sample amounts and water volumes. Some instructions specified amounts that would produce sample concentrations well above the threshold where cross-reactivity becomes problematic. The result was a generation of users and programs experiencing false positives and attributing them to "bad strips" or "unreliable tests" when the actual problem was inconsistent sample preparation.

The solution to inaccurate dilution is standardized measurement. If every user scoops the same amount of substance and adds it to the same volume of water, every test runs within the validated concentration range and cross-reactivity-driven false positives disappear. This is why calibrated micro-scoops were introduced into fentanyl test strip kits. Subcheck was among the first companies to include a pre-measured scoop in every kit — designed to collect approximately 10 milligrams of powder or crusite material, paired with a pre-filled water vessel containing the correct volume. The scoop physically prevents over-measurement: its geometry limits how much substance can be collected, removing the guesswork that caused false positives. The practice of including standardized measurement tools has since spread across the industry, and multiple organizations now recommend scoop-based measurement over visual estimation.

Some test strip brands and distributors market their products with claims of "zero false positives" or "no cross-reactivity." These claims require careful examination. In many cases, strips marketed this way achieve low false positive rates not through superior antibody specificity but through lower sensitivity — their detection threshold is set higher (around 10 mg/mL versus 2 mg/mL for more sensitive strips), which means they are less likely to cross-react with non-target compounds but also less likely to detect fentanyl at lower concentrations. A strip with a 10 mg/mL threshold will produce fewer false positives than a strip with a 2 mg/mL threshold — but it will also miss fentanyl-positive samples that fall between those two thresholds. This is a tradeoff between false positive rate and false negative rate, and lower sensitivity is not an improvement — it is a different failure mode. The better solution is to maintain high sensitivity (catching fentanyl at lower concentrations) while controlling dilution to prevent false positives. This requires proper sample preparation tools, not reduced detection capability.

False positives on fentanyl test strips are a sample preparation problem, not a strip performance problem. When the user adds the right amount of substance to the right amount of water, the immunoassay performs within its validated range and false positives are eliminated across all substance types. The prescription is simple: use a calibrated scoop (do not estimate by eye), use a measured water volume (do not pour from a tap), dissolve fully before dipping, and read at the recommended time. Programs that have adopted standardized kits with included measurement tools report dramatic reductions in false positive complaints from their participants. If your program is experiencing high false positive rates, the first question to ask is not "are these strips defective?" but "are our users diluting correctly?" In almost every case, the answer points to sample preparation.